New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Heatwurx Inc.

PCSA

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

1.67 0.03 −1.76%
Market cap
$4.8M
P/E
n/m
Fwd P/E FY16e
—
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
0.4×
Payout ratio
—

Ratios over time Q4 FY25 to Q3 FY26

Returns on capital

ROIC was 0.0% in Q3 FY26, the highest of these four quarters. ROE, at 220.1%, is far above it because equity is small against the capital the business uses.

ROEROIC
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
ROE−373.0%−465.0%−464.2%220.1%
ROIC−21857.0%−1064.3%0.0%0.0%

Debt

Net debt is 0.98× a year’s EBITDA. Debt is 0.00× equity.

Debt / equityNet debt / EBITDA
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Debt / equity0.0×0.0×0.0×0.0×
Net debt / EBITDA1.5×0.5×0.1×1.0×
Older periods Dec '25 Mar '26 Jun '26 Sep '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
2.48 0.85 0.08 96.73
Current Ratio
2.54 0.98 0.87 97.70
Net Debt/EBITDA
1.50 0.51 0.08 0.98
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.86 1.06 0.61 0.03
Capex/Depreciation
(4,250.00) (1,666.67) 620.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.15 0.35 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(2.22) (1.37) (0.73) (1.74)
Capex per Share
(0.65) (0.19) 0.07 0.00
Free Cash Flow per Share
(2.86) (1.56) (0.66) (1.74)
Cash per Share
4.23 0.64 0.07 60.59
Shareholders Equity per Share
4.26 0.97 (0.12) (60.99)
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
4.26 0.97 (0.12) (60.99)
Free Cash Flow
(3.75) (4.09) (1.81) (5.18)
Working Capital
3.43 (0.04) (0.32) 180.15
Capital Expenditures
(0.85) (0.50) 0.19 0.00
Net Current Asset Value
3.43 (0.04) (0.32) (181.39)
EV/EBIT
— — — —
Capex to Sales
0.00 0.00 0.00 0.00
Other line items
Average Payables
0.97 0.70 1.22 0.96
Average Assets
5.52 4.67 5.13 94.80
Average Common Equity
3.64 3.03 2.89 (87.78)

Fold the line items

Columns are period end dates · fundamentals updated 18 Nov 2026